Chinese Partner HBM Initiated First Dosing of Phase 2 trials of HL161 in MG and ITP in China
Chinese Partner HBM Initiated First Dosing of Phase 2 trials of HL161 in MG and ITP in China
HL161(batoclimab) Demonstrated Positive Top-line Results in Phase 2 Clinical Trial in Myasthenia Gravis
HL161(batoclimab) Demonstrated Positive Top-line Results in Phase 2 Clinical Trial in Myasthenia Gra..
HanAll Biopharma recorded KRW 22.6 billion and KRW 1.6 billion in sales and operating income for the second quarter
HanAll Biopharma recorded KRW 22.6 billion and KRW 1.6 billion in sales and operating income for the..
HanAll Biopharma Appoints Sean Jeong as CEO of HPI, HanAll’s US Subsidiary
HanAll Biopharma Appoints Sean Jeong as CEO of HPI, HanAll’s US Subsidiary
HBM, HanAll Biopharma’s Chinese Partner, Begins Clinical Trials for Batoclimab with NMOSD Patients
HBM, HanAll Biopharma’s Chinese Partner, Begins Clinical Trials for Batoclimab with NMOSD Patients
Immunovant, HanAll’s partner, Announces Topline data from Phase 2 for IMVT-1401 in TED
Immunovant, HanAll’s partner, Announces Topline data from Phase 2 for IMVT-1401 in TED